1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 治療タイプ別スニペット
3.2. 投与経路別スニペット
3.3. 患者タイプ別スニペット
3.4. 販売チャネル別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 若年性皮膚筋炎の有病率の上昇
4.1.1.2. 市場参入企業による製品開発活動の活発化
4.1.2. 阻害要因
4.1.2.1. 承認された治療法の欠如
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. 価格分析
5.3. 規制分析
5.4. アンメット・ニーズ
5.5. PESTEL分析
5.6. 特許分析
5.7. SWOT分析
5.8. 疫学
6. 治療タイプ別
6.1. はじめに
6.1.1. 治療タイプ別市場規模分析および前年比成長率分析(%) 6.1.2.
6.1.2. 市場魅力度指数(治療タイプ別
6.2. 副腎皮質ステロイド*市場
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. 免疫抑制剤
6.2.3.1. メトトレキサート
6.2.3.2. シクロスポリン
6.2.3.3. ミコフェノール酸モフェチル
6.2.3.4. その他
6.3. 免疫グロブリン静注(IVIG)
6.4. ヒドロキシクロロキン
6.5. 標的療法
6.5.1. インフリキシマブ
6.5.2. リツキシマブ
6.5.3. その他
6.6. その他
7. 投与経路別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析(%)、投与経路別
7.1.2. 市場魅力度指数(投与経路別
7.2. 経口*剤
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 非経口剤
7.4. その他
8. 患者タイプ別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析(%)、患者タイプ別
8.1.2. 市場魅力度指数(患者タイプ別
8.2. 男性*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 女性
9. 流通チャネル別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析(%), 流通チャネル別
9.1.2. 市場魅力度指数(流通チャネル別
9.2. 病院薬局
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 小売薬局
9.4. オンライン薬局
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析(%)(治療タイプ別
10.2.4. 市場規模分析および前年比成長率分析(%)、投与経路別
10.2.5. 市場規模分析および前年比成長率分析(%), 患者タイプ別
10.2.6. 市場規模分析および前年比成長率分析(%), 流通チャネル別
10.2.7. 市場規模分析および前年比成長率分析(%), 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析(%)(治療タイプ別
10.3.4. 市場規模分析および前年比成長率分析(%)、投与経路別
10.3.5. 市場規模分析および前年比成長率分析(%), 患者タイプ別
10.3.6. 市場規模分析および前年比成長率分析(%):流通チャネル別
10.3.6.1. 市場規模分析および前年比成長率分析(%), 国別
10.3.6.2. ドイツ
10.3.6.3. イギリス
10.3.6.4. フランス
10.3.6.5. イタリア
10.3.6.6. スペイン
10.3.6.7. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 市場規模分析および前年比成長率分析(%)(治療タイプ別
10.4.4. 市場規模分析および前年比成長率分析(%)、投与経路別
10.4.5. 市場規模分析および前年比成長率分析(%), 患者タイプ別
10.4.6. 市場規模分析および前年比成長率分析(%):流通チャネル別
10.4.6.1. 市場規模分析および前年比成長率分析(%), 国別
10.4.6.2. ブラジル
10.4.6.3. アルゼンチン
10.4.6.4. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 市場規模分析および前年比成長率分析(%)(治療タイプ別
10.5.4. 市場規模分析および前年比成長率分析(%)、投与経路別
10.5.5. 市場規模分析および前年比成長率分析(%)、患者タイプ別
10.5.6. 市場規模分析および前年比成長率分析(%):流通チャネル別
10.5.7.
10.5.7.1. 市場規模分析および前年比成長率分析(%), 国別
10.5.7.2. 中国
10.5.7.3. インド
10.5.7.4. 日本
10.5.7.5. 韓国
10.5.7.6. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 市場規模分析および前年比成長率分析(%)(治療タイプ別
10.6.4. 市場規模分析および前年比成長率分析(%)、投与経路別
10.6.5. 市場規模分析および前年比成長率分析(%), 患者タイプ別
10.6.6. 市場規模分析および前年比成長率分析(%):流通チャネル別
11. 競合情勢
11.1. 競争シナリオ
11.2. 市場ポジショニング/シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Teva Pharmaceuticals USA, Inc.*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. Pfizer Inc.
12.3. Sanofi
12.4. Novartis AG
12.5. F. Hoffmann-La Roche Ltd
12.6. Octapharma USA, Inc.
12.7. AbbVie Inc.
12.8. Horizon Therapeutics plc
12.9. Viatris Inc.
12.10. Sandoz AG (*リストは除く)
13. 付録
13.1. 会社概要とサービス
13.2. お問い合わせ
The Global Juvenile Dermatomyositis Treatment Market reached US$ 71.15 million in 2023 and is expected to reach US$ 101.93 million by 2031, growing at a CAGR of 4.6% during the forecast period 2024-2031.
Juvenile dermatomyositis is a rare autoimmune inflammatory condition in children affecting primarily skin and skeletal muscles. The condition is chronic and the frequent symptoms are muscle weakness, myalgia, skin lesions, pruritis, fever, dysphagia, and respiratory and GI symptoms. The condition is rare and accounts for nearly 4,000 prevalent cases in the U.S.
There is no specific treatment available to cure the condition, however, certain therapeutic options such as corticosteroids, immunosuppressants, and biologic drugs are available which prevent the disease progression and aid the patients to live healthy and longer lives.
Market Dynamics: Drivers
Rising product development activities by market players
Juvenile dermatomyositis is a rare condition affecting children below 18 years of age. There is no specific treatment option currently available for JDM, and the existing therapies focus on alleviating the symptoms and preventing the disease progression. There are several product development activities, which if successful may provide broad-spectrum treatment options to the patients. These novel products may provide better therapeutic outcomes and improve the overall treatment rate-propelling the market positively in the forecast period.
For instance, biological therapies are currently revolutionizing the rare disease therapeutics market. For the treatment of juvenile dermatomyositis, Rituximab, abatacept, and infliximab were proven to be efficacious in treating patients with severe skin involvement, calcinosis, and resistant diseases. These biological therapies are currently a promising area for patients with severe symptoms.
Moreover, Baricitinib a janus kinase (JAK) inhibitor is currently under phase 2 clinical trials for the treatment of new-onset juvenile dermatomyositis. The study is anticipated to be finished by the end of 2026. This MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM).
Additionally, in September 2024, the U.S. Food and Drug Administration (FDA) granted a rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08 developed by Cartesian Therapeutics, Inc. is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product currently ready for phase 2 basket study (multiple indications) for neurology and rheumatology autoimmune indications, including JDM.
Restraints
The market for juvenile dermatomyositis treatments is restrained by several factors such as side effects associated with the use of corticosteroids, and the rarity of the condition-limited patient population available for product development activities such as clinical trials.
Market Segment Analysis
The global juvenile dermatomyositis treatment market is segmented based on treatment type, route of administration, patient type, distribution channel, and region.
Corticosteroids in the treatment type segment accounted for approximately 65.3% of the global juvenile dermatomyositis treatment market share.
Corticosteroids, especially prednisone are most widely used as first-line agents for treating juvenile dermatomyositis. For juvenile patients who are initially diagnosed with dermatomyositis, oral prednisone is given at higher doses for a longer duration of ~4 months, followed by other therapies such as methotrexate, cyclosporine, or other immunosuppressants with or without prednisone.
The main goal of treatment is to eliminate inflammation, restore muscle function, and further prevent the disability. According to the American College of Rheumatology, high-dose oral or intravenous corticosteroids are chosen as first-line agents for the condition. According to the Arthritis Foundation of America, corticosteroids are often used as a first-line therapy for juvenile dermatomyositis, due to their powerful anti-inflammatory effects and fast-acting capability.
Market Geographical Share
North America dominates the global juvenile dermatomyositis treatment market with a share of XX% in 2023, and growing at a CAGR of 43.5% in the forecast period
North America dominates the global juvenile dermatomyositis treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.
For instance, in August 2024, an article published in MDPI journals on juvenile idiopathic inflammatory myopathies (JIIM) stated that juvenile dermatomyositis is the most common form of JIIM in the U.S., accounting for more than 80% of cases. The annual incidence of juvenile dermatomyositis is estimated to be between 1.9 to 4.1 per million children in the U.S. As per dataM estimates, the annual incidence cases are approximately 230-240 cases in the U.S.
The region is at the forefront of developing novel therapies for JDM. With the favorable regulatory policies, and the greater demand for advanced care, innovator companies focus on developing and launching their product first in this region. As a result, the patient population gets advanced access to these novel therapies. For instance, on September 9, 2024, the U.S. FDA provided a rare pediatric designation for Descartes-08 to treat juvenile dermatomyositis. The drug, if completes clinical studies, may get launched first in the U.S. market.
Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.
Market Segmentation
By Treatment Type
Corticosteroids
Immunosuppressants
Methotrexate
Cyclosporine
Mycophenolate Mofetil
Others
Intravenous Immunoglobulin (IVIG)
Hydroxychloroquine
Targeted Therapies
Infliximab
Rituximab
Abatacept
Others
Others
By Route of Administration
Oral
Parenteral
Others
By Patient Type
Male
Female
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major players in the juvenile dermatomyositis treatment market include Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Octapharma USA, Inc., AbbVie Inc., Horizon Therapeutics plc, Viatris Inc. and Sandoz AG among others.
Why Purchase the Report?
To visualize the global juvenile dermatomyositis treatment
Market Segmentation based on treatment type, route of administration, patient type, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of juvenile dermatomyositis treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global juvenile dermatomyositis treatment market report would provide approximately 70 tables, 64 figures, and 212 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Patient Type
3.4. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of juvenile dermatomyositis
4.1.1.2. Rising product development activities by market players
4.1.2. Restraints
4.1.2.1. Lack of approved therapies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Unmet Needs
5.5. PESTEL Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. Epidemiology
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Corticosteroids*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Immunosuppressants
6.2.3.1. Methotrexate
6.2.3.2. Cyclosporine
6.2.3.3. Mycophenolate Mofetil
6.2.3.4. Others
6.3. Intravenous Immunoglobulin (IVIG)
6.4. Hydroxychloroquine
6.5. Targeted Therapies
6.5.1. Infliximab
6.5.2. Rituximab
6.5.3. Others
6.6. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
7.4. Others
8. By Patient Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Male*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Female
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.2. Germany
10.3.6.3. UK
10.3.6.4. France
10.3.6.5. Italy
10.3.6.6. Spain
10.3.6.7. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.2. Brazil
10.4.6.3. Argentina
10.4.6.4. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7.
10.5.7.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.2. China
10.5.7.3. India
10.5.7.4. Japan
10.5.7.5. South Korea
10.5.7.6. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceuticals USA, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer Inc.
12.3. Sanofi
12.4. Novartis AG
12.5. F. Hoffmann-La Roche Ltd
12.6. Octapharma USA, Inc.
12.7. AbbVie Inc.
12.8. Horizon Therapeutics plc
12.9. Viatris Inc.
12.10. Sandoz AG (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us
*** 若年性皮膚筋炎治療の世界市場に関するよくある質問(FAQ) ***
・若年性皮膚筋炎治療の世界市場規模は?
→DataM Intelligence社は2023年の若年性皮膚筋炎治療の世界市場規模を7,115万米ドルと推定しています。
・若年性皮膚筋炎治療の世界市場予測は?
→DataM Intelligence社は2031年の若年性皮膚筋炎治療の世界市場規模を1億193万米ドルと予測しています。
・若年性皮膚筋炎治療市場の成長率は?
→DataM Intelligence社は若年性皮膚筋炎治療の世界市場が2024年~2031年に年平均4.6%成長すると展望しています。
・世界の若年性皮膚筋炎治療市場における主要プレイヤーは?
→「Teva Pharmaceuticals USA, Inc.、Pfizer Inc.、Sanofi、Novartis AG、F. Hoffmann-La Roche Ltd.、Octapharma USA, Inc.、AbbVie Inc.、Horizon Therapeutics plc、Viatris Inc.、Sandoz AGなど ...」を若年性皮膚筋炎治療市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/